Stockscreener 앱 받기
150.97
0.81%
-1.24
시간 외 거래:
152.00
1.03
+0.68%
Biogen Inc 주식(BIIB)의 최신 뉴스
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
Can BMYs Neuroscience Portfolio Help to Diversify Its Business? - The Globe and Mail
Biogen stock price target lowered to $217 from $219 at RBC Capital - Investing.com UK
Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $217.00 - MarketBeat
Central Nervous System Biomarkers Market Growth & Industry - openPR.com
Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat
Biogen Inc. $BIIB Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Ascent Group LLC Takes $341,000 Position in Biogen Inc. $BIIB - MarketBeat
Biogen Says Investors Can't Expand Alzheimer's Drug Suit - Law360
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syn - PharmiWeb.com
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - Yahoo Finance
Bioarctic's Leqembi Maintenance Therapy Launched in the United States - MarketScreener
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus
Leqembi Iqlik subcutaneous injection now available in US By Investing.com - Investing.com Australia
Biogen Inc. stock underperforms Monday when compared to competitors - MSN
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S. - GuruFocus
Leqembi Iqlik subcutaneous injection now available in US - Investing.com
Eisai and Biogen Launch LEQEMBI Companion™ Program to Enhance Resources for Alzheimer's Disease Treatment - Quiver Quantitative
Biogen told to pay $124M in patent dispute with Genentech - Fierce Pharma
Rothschild & Co Redburn Increases Biogen (NASDAQ:BIIB) Price Target to $150.00 - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Biogen to $150 From $149, Maintains Neutral Rating - MarketScreener
In Vitro Monoclonal Antibodies Market to hit US$ 8.4 Billion - openPR.com
Acetylcholinesterase Inhibitors Market to hit US$ 9.03 Billion - openPR.com
Can Biogen Inc. stock double in next 5 yearsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Grimes & Company Inc. Sells 18,310 Shares of Biogen Inc. $BIIB - MarketBeat
J. Safra Sarasin Holding AG Sells 7,635 Shares of Biogen Inc. $BIIB - MarketBeat
Mirae Asset Global Investments Co. Ltd. Raises Holdings in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. stock a defensive play in 2025Oil Prices & Verified Swing Trading Watchlist - newser.com
A Look at Biogen (BIIB) Valuation Following Australian LEQEMBI Approval and Fresh Analyst Optimism - simplywall.st
Biogen Idec : Biogen Idec Named Top Employer by Science Magazine - MarketScreener
Day 6 of Gains Streak for Biogen Stock with 18% Return (vs. 4.6% YTD) [10/3/2025] - Trefis
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biogen (BIIB) Gains as LEQEMBI Wins Australian Approval for Early Alzheimer’s Treatment - simplywall.st
[Updated 2026] Biotechnology Market Size & Sector Scope 2032 - openPR.com
Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT - MSN
Biogen must pay $88 million more for use of infamous Cabilly patent - IAM Patent
Could Eisai Partnership and New LEQEMBI Approval Reshape Biogen's (BIIB) Alzheimer's Strategy? - simplywall.st
United States SMN1 Gene Replacement Market is expected to reach - openPR.com
Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength? - Yahoo Finance
Biogen Inc. $BIIB Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Greenleaf Trust Raises Holdings in Biogen Inc. $BIIB - MarketBeat
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com
Biogen’s Global Expansion and Promising Data Fuel Alzheimer’s Treatment Optimism - AD HOC NEWS
Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns - FinancialContent
Biogen owes Genentech $88 million in MS drug dispute, US judge says - Reuters
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years - Benzinga
Biogen’s Bold Moves: Navigating the Market Waves - StocksToTrade
Biogen (NASDAQ:BIIB) Trading 8.1% HigherStill a Buy? - MarketBeat
Biogen Receives Regulatory Approvals: Stock to Surge? - timothysykes.com
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Amgen and Biogen settle patent dispute over Prolia and Xgeva biosimilars - Seeking Alpha
Transcript : Biogen Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 10 - MarketScreener
United States Acute Cerebral Ischemic Stroke Drug Market to grow - openPR.com
Boston M&A in August Biogen, GE Vernova and Desktop Metal - The Business Journals
Generali Investments CEE investicni spolecnost a.s. Buys 11,695 Shares of Biogen Inc. $BIIB - MarketBeat
Signaturefd LLC Has $574,000 Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Told To Pay Genentech $88M After IP Royalties Mistrial - Law360
RBC Capital Keeps Their Buy Rating on Biogen (BIIB) - The Globe and Mail
0.80%
1.26%
자본화:
|
볼륨(24시간):